• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

将可溶性蛋白质引入抗原加工和呈递的I类途径。

Introduction of soluble protein into the class I pathway of antigen processing and presentation.

作者信息

Moore M W, Carbone F R, Bevan M J

机构信息

Department of Immunology, Research Institute of Scripps Clinic, La Jolla, California 92037.

出版信息

Cell. 1988 Sep 9;54(6):777-85. doi: 10.1016/s0092-8674(88)91043-4.

DOI:10.1016/s0092-8674(88)91043-4
PMID:3261634
Abstract

In order to investigate how peptides associate with class I major histocompatibility complex (MHC) glycoproteins intracellularly, we generated cytotoxic T lymphocytes (CTL) specific for a readily available soluble protein in association with class I. C57BL/6 (H-2b) mice immunized against a syngeneic tumor cell transfected with chicken ovalbumin (OVA) cDNA gave rise to H-2Kb-restricted CTL specific for the OVA258-276 peptide. This synthetic peptide and CNBr fragments of OVA (242-285 and 242-273) were able to target H-2b cells for lysis by the CTL in a 3 hr assay. Cells incubated with native OVA for up to 24 hr did not become sensitized for recognition and lysis. However, when OVA was introduced directly into the cytoplasm of cells by the osmotic lysis of pinosomes, the Kb restricted determinant formed readily.

摘要

为了研究肽在细胞内如何与I类主要组织相容性复合体(MHC)糖蛋白结合,我们制备了对一种易于获得的与I类相关的可溶性蛋白具有特异性的细胞毒性T淋巴细胞(CTL)。用转染了鸡卵清蛋白(OVA)cDNA的同基因肿瘤细胞免疫的C57BL/6(H-2b)小鼠产生了对OVA258-276肽具有特异性的H-2Kb限制性CTL。在3小时的实验中,这种合成肽以及OVA的溴化氰片段(242-285和242-273)能够使H-2b细胞被CTL裂解。与天然OVA孵育长达24小时的细胞不会变得对识别和裂解敏感。然而,当通过胞饮体的渗透裂解将OVA直接引入细胞的细胞质中时,Kb限制性决定簇很容易形成。

相似文献

1
Introduction of soluble protein into the class I pathway of antigen processing and presentation.将可溶性蛋白质引入抗原加工和呈递的I类途径。
Cell. 1988 Sep 9;54(6):777-85. doi: 10.1016/s0092-8674(88)91043-4.
2
Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization.通过体内肽免疫诱导卵清蛋白特异性细胞毒性T细胞。
J Exp Med. 1989 Mar 1;169(3):603-12. doi: 10.1084/jem.169.3.603.
3
Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides.通过肽的初次体外刺激诱导细胞毒性T淋巴细胞。
J Exp Med. 1988 Jun 1;167(6):1767-79. doi: 10.1084/jem.167.6.1767.
4
Class I-restricted presentation occurs without internalization or processing of exogenous antigenic peptides.I类分子限制的提呈无需对外源抗原肽进行内化或加工即可发生。
J Immunol. 1989 Feb 15;142(4):1079-83.
5
Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help.在缺乏CD4+ T细胞辅助的情况下,古脂质体通过外源性胞质途径诱导对包裹的可溶性蛋白产生长期的CD8+ 细胞毒性T细胞反应。
J Immunol. 2000 Nov 1;165(9):5177-85. doi: 10.4049/jimmunol.165.9.5177.
6
Electroporation and commercial liposomes efficiently deliver soluble protein into the MHC class I presentation pathway. Priming in vitro and in vivo for class I-restricted recognition of soluble antigen.电穿孔和商用脂质体可有效地将可溶性蛋白质递送至MHC I类呈递途径。在体外和体内进行致敏以实现对可溶性抗原的I类限制性识别。
J Immunol Methods. 1993 Mar 15;160(1):49-57. doi: 10.1016/0022-1759(93)90007-t.
7
The effect of mutations in the MHC class I peptide binding groove on the cytotoxic T lymphocyte recognition of the Kb-restricted ovalbumin determinant.MHC I类肽结合槽中的突变对细胞毒性T淋巴细胞对Kb限制性卵清蛋白决定簇识别的影响。
Eur J Immunol. 1990 Nov;20(11):2431-7. doi: 10.1002/eji.1830201111.
8
Class I restricted CTL recognition of a soluble protein delivered by liposomes containing lipophilic polylysines.
J Immunol Methods. 1992 Aug 10;152(2):237-43. doi: 10.1016/0022-1759(92)90145-j.
9
Injection of detergent-denatured ovalbumin primes murine class I-restricted cytotoxic T cells in vivo.注射经去污剂变性的卵清蛋白可在体内引发小鼠I类限制性细胞毒性T细胞。
Eur J Immunol. 1994 Sep;24(9):2068-72. doi: 10.1002/eji.1830240920.
10
Tetramer-blocking assay for defining antigen-specific cytotoxic T lymphocytes using peptide-MHC tetramer.使用肽-MHC四聚体定义抗原特异性细胞毒性T淋巴细胞的四聚体阻断试验。
Cancer Sci. 2006 Feb;97(2):148-54. doi: 10.1111/j.1349-7006.2006.00149.x.

引用本文的文献

1
Harnessing an integrated glyco-nanovaccine technology for enhanced cancer immunotherapy.利用集成的糖纳米疫苗技术增强癌症免疫疗法。
Commun Med (Lond). 2025 Aug 29;5(1):378. doi: 10.1038/s43856-025-01102-3.
2
Lytic polyplex vaccines enhance antigen-specific cytotoxic T cell response through induction of local cell death.溶细胞性多聚体疫苗通过诱导局部细胞死亡增强抗原特异性细胞毒性T细胞反应。
Adv Ther (Weinh). 2021 Aug;4(8). doi: 10.1002/adtp.202100005. Epub 2021 Feb 22.
3
ANV600 is a novel PD-1 targeted IL-2Rβγ agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy.
ANV600是一种新型的靶向程序性死亡受体1(PD-1)的白细胞介素-2受体βγ激动剂,可选择性扩增肿瘤抗原特异性T细胞,并增强程序性死亡受体1(PD-1)检查点抑制剂疗法的效果。
J Immunother Cancer. 2025 Jul 15;13(7):e011905. doi: 10.1136/jitc-2025-011905.
4
Immunization with peptide encapsulated within synthetic spores activates T cell responses and reduces tumor growth.用包裹在合成孢子内的肽进行免疫可激活T细胞反应并减少肿瘤生长。
bioRxiv. 2025 Feb 27:2025.02.27.640614. doi: 10.1101/2025.02.27.640614.
5
High Antigenicity for T Cells Confers Resistance to PD-1 Blockade Therapy via High PD-1 Expression in T Cells.T细胞的高抗原性通过T细胞中高表达的PD-1赋予对PD-1阻断疗法的抗性。
Cancer Sci. 2025 May;116(5):1214-1226. doi: 10.1111/cas.70029. Epub 2025 Feb 27.
6
Tumor-Specific Antigen Delivery for T-cell Therapy via a pH-Sensitive Peptide Conjugate.通过pH敏感肽偶联物进行肿瘤特异性抗原递送用于T细胞治疗
Mol Cancer Ther. 2025 Jan 2;24(1):105-117. doi: 10.1158/1535-7163.MCT-23-0809.
7
Jonathan Yewdell Discusses Viral Immunology, Vaccine Development, Navigating a Scientific Career, and Offers Perspectives on Transforming Scientific Publishing and Research Education.乔纳森·尤德尔讨论了病毒免疫学、疫苗开发、科学职业生涯规划,并就科学出版和研究教育的变革发表了看法。
Pathog Immun. 2024 Sep 27;9(2):94-134. doi: 10.20411/pai.v9i2.753. eCollection 2024.
8
Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity.免疫蛋白酶体激活可扩展MHC I类免疫肽组,揭示新抗原,并增强T细胞抗骨髓瘤活性。
Mol Cancer Ther. 2024 Dec 3;23(12):1743-1760. doi: 10.1158/1535-7163.MCT-23-0931.
9
Neoantigen-specific T cell help outperforms non-specific help in multi-antigen DNA vaccination against cancer.在针对癌症的多抗原DNA疫苗接种中,新抗原特异性T细胞辅助比非特异性辅助表现更优。
Mol Ther Oncol. 2024 Jun 15;32(3):200835. doi: 10.1016/j.omton.2024.200835. eCollection 2024 Sep 19.
10
HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity.HDAC6 抑制作用释放 HR23B 以激活蛋白酶体,扩大肿瘤免疫肽组并放大 T 细胞抗骨髓瘤活性。
Cancer Res Commun. 2024 Jun 18;4(6):1517-1532. doi: 10.1158/2767-9764.CRC-23-0528.